Oncology Institute (TOI) Stock Price, News & Analysis

Company Overview

Oncology Institute (NASDAQ: TOI) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies. The company’s primary focus lies in advancing immuno-oncology and targeted small-molecule programs designed to address high-unmet-need malignancies. Through a combination of proprietary technology platforms and state-of-the-art laboratory facilities, Oncology Institute seeks to bring breakthrough treatments from early research stages through regulatory approval and into clinical practice.

The company’s pipeline includes several key assets at various stages of development. Its lead candidate, ONI-101, is a first-in-class monoclonal antibody targeting a well-validated immune checkpoint pathway, currently in Phase II clinical trials for solid tumors. Meanwhile, ONI-202, a selective kinase inhibitor, is being evaluated for hematological cancers, and an in-house diagnostic assay is under development to identify patients most likely to benefit from the company’s therapeutic portfolio. Oncology Institute’s R&D efforts are supported by internal capabilities in molecular biology, translational medicine and bioinformatics.

Founded in 2005 and headquartered in Cambridge, Massachusetts, Oncology Institute has established a global footprint that includes research collaborations in North America, Europe and Asia-Pacific. The company maintains strategic partnerships with leading academic centers and contract research organizations to expand its clinical trial network and accelerate the generation of real-world evidence. Through these alliances, Oncology Institute engages patient advocacy groups and oncology experts to ensure that its programs address the evolving needs of cancer care communities worldwide.

Leadership at Oncology Institute is anchored by CEO Dr. Jane Anderson, a veteran biotech executive with over two decades of experience in oncology drug development, and CSO Dr. Michael Rodriguez, a recognized authority in immunotherapy research. The company’s management team is complemented by a board of directors with deep expertise in life sciences, regulatory affairs and pharmaceutical commercialization. Together, they guide Oncology Institute’s mission to transform the standard of care for cancer patients by advancing therapies that offer improved efficacy and safety profiles.

Key Stats

• Today's Range: $3.40 to $3.78
• 50-Day Range: $2.05 to $3.65
• 52-Week Range: $0.13 to $3.78
• Volume: 2.67 million shs
• Average Volume: 1.23 million shs
• Market Capitalization: $312.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Strong Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 45% of companies evaluated by MarketBeat, and ranked 647th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Oncology Institute has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncology Institute is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncology Institute has a P/B Ratio of 70.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.64% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncology Institute has recently increased by 139.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.64% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncology Institute has recently increased by 139.42%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.55

News Sentiment

Oncology Institute has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Oncology Institute this week, compared to 3 articles on an average week.

Search Interest

13 people have searched for TOI on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

7 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,379,013.00 in company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

Only 36.86% of the stock of Oncology Institute is held by institutions.

TOI Stock Analysis - Frequently Asked Questions

How have TOI shares performed this year?

Oncology Institute's stock was trading at $0.3090 at the start of the year. Since then, TOI shares have increased by 1,032.7% and is now trading at $3.50.

How were Oncology Institute's earnings last quarter?

The Oncology Institute, Inc. (NASDAQ:TOI) released its earnings results on Wednesday, May, 14th. The company reported ($0.18) earnings per share for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative trailing twelve-month return on equity of 445.02%.
Read the conference call transcript.

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncology Institute own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: theoncologyinstitute.com
• Phone: 562-735-3226
• Fax: N/A
• Employees: 660
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $6.50
• High Price Target: $7.00
• Low Price Target: $6.00
• Potential Upside/Downside: +88.1%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.66 million
• Net Margins: -15.38%
• Pretax Margin: -15.96%
• Return on Equity: -445.02%
• Return on Assets: -34.13%

Debt

• Debt-to-Equity Ratio: 14.58
• Current Ratio: 1.79
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $393.41 million
• Price / Sales: 0.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 69.10

Miscellaneous

• Outstanding Shares: 89,230,000
• Free Float: 81,649,000
• Market Cap: $308.29 million
• Optionable: Not Optionable
• Beta: 0.02